Radiopharm Theranostics (RADX) Equity Average (2025)
Radiopharm Theranostics (RADX) has disclosed Equity Average for 1 consecutive years, with $35.1 million as the latest value for Q2 2025.
- Quarterly Equity Average changed N/A to $35.1 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $35.1 million through Jun 2025, changed N/A year-over-year, with the annual reading at $35.1 million for FY2025, 3.71% down from the prior year.
- Equity Average for Q2 2025 was $35.1 million at Radiopharm Theranostics.
- The five-year high for Equity Average was $35.1 million in Q2 2025, with the low at $35.1 million in Q2 2025.